key: cord-0917103-l61qk9ii
authors: Keeling, Elizabeth; Daly, Selene; McKenna, Dermot B.
title: Dermatology patients’ knowledge and concerns regarding their immunomodulatory medication during the COVID‐19 pandemic
date: 2020-05-01
journal: Dermatol Ther
DOI: 10.1111/dth.13488
sha: 7ddc2f4fcde6adda497480147aa1a08600520f00
doc_id: 917103
cord_uid: l61qk9ii

nan

Dermatology patients' knowledge and concerns regarding their immunomodulatory medication during the COVID-19 pandemic.

Dear Editor, Higher rates of morbidity and mortality due to COVID-19, caused by infection with SARS-Corona Virus-2 (SARS-CoV-2) are associated with increasing age, gender and a variety of comorbidities. Given the apparent risk of infection from viral diseases in patients receiving immunomodulatory medications we surveyed a sample of our dermatology patients on these treatments regarding their knowledge and perceived risk to the novel coronavirus. The phone-call survey was carried out from 27/03/20 to 03/04/20 and included questions on demographics, co-morbidities, immunomodulatory agent and concern regarding immunosuppression. Self-isolation, knowledge of viral symptoms, cocooning/sheltering and sourcing of information pertaining to COVID-19 was assessed. All 103 patients invited to participate completed the questionnaire. Information pertaining to patient demographics, underlying disease and immunomodulatory treatments is shown in Table 1 .

Over 90% were aware of one or more of the symptoms of COVID-19. Overall 53% of patients considered themselves at high risk of the infection due to their medication (biologics, 62%; methotrexate, 53%; and Apremilast, 20%). Of those, 68% believed This article is protected by copyright. All rights reserved. they were more likely to contract the virus while 84% sensed that their illness would be more severe. Three patients were noted to be in self-isolation, two due to symptoms of COVID-19, while the other had been in contact with a presumed case pending swabbing. None of these patients required hospitalisation. Two of these patients had continued their medication.

The majority of patients (73%) had not sought advice on their medication since the COVID-19 pandemic outbreak. Of those who sought advice, most contacted their general practitioner (45%) followed by pharmacist (22%), nurse (11%) or pharmaceutical helpline (22%). No patient contacted the dermatology unit for advice.

Others reported accessing information elsewhere: 13% from social media, 12% from the Irish Health Service Executive website, 13% from television or radio. Of those still attending their workplace, 15% were front line including healthcare.

Overall 90% of patients had continued their medication while 10% (mainly biologics) stopped due to COVID-19 concerns. These patients stopped on their own initiative, not on advice received from health care professionals or information sources discussed above. Fifty-one percent reported that they would withhold treatment if they became symptomatic, 41% would not discontinue unless advised by their dermatologist, with 8% stating they would not stop under any circumstance. Almost all (94%) patients feared a flare of their underlying condition should they stop, while 6% felt they may have difficulty re-accessing their medication in the future if they This article is protected by copyright. All rights reserved. infection. This expert advice also states it is reasonable to reduce the dose or discontinue treatment for 2 weeks in those not formally diagnosed with COVID-19 in the presence of cold/flu symptoms. The guidelines suggest the benefit-to-risk ratio of immunomodulators needs to be considered carefully in patients at higher risk from COVID-19 due to age or co-morbidities. This survey highlights a high proportion of dermatology patients on immunomodulators have co-morbidities associated with a more severe COVID-19 illness (Table 1) . Given the likely prolonged nature of this pandemic clinicians may need to consider risks and benefits of immunomodulators for each individual and communicate this to the patient. 

Guidance on the Use of Systemic Therapy for Patients with Psoriasis/Atopic Dermatitis During the Covid-19 (Sars-Cov-2, Coronavirus) Pandemic